Insider plans Rule 144 sale of 32,077 shares

An affiliate of the issuer has filed a notice of proposed sale of 32,077 shares of common stock under Rule 144.

Rhea-AI Filing Summary

An affiliate of the issuer has filed a notice of proposed sale of 32,077 shares of common stock under Rule 144. The planned sale, with an aggregate market value of $163,271.93, is to be executed through Maxim Group LLC on or about 01/23/2026 on the Nasdaq exchange.

The 32,077 shares were acquired on 01/23/2026 via an RSU award from the issuer, with payment in the form of the reporting person’s continued employment and the award vesting and settling in stock on that date. The filing notes that there were 273,919,373 shares of this class of common stock outstanding.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does this Form 144 filing for TSHA relate to?

It relates to a proposed sale under Rule 144 of 32,077 shares of common stock of the issuer by or for the account of a person associated with the company.

How many TSHA shares are planned to be sold and at what value?

The notice covers a proposed sale of 32,077 common shares with an aggregate market value of $163,271.93, as stated in the filing.

When and where are the TSHA shares expected to be sold?

The approximate date of sale is listed as 01/23/2026, with trades to occur on the Nasdaq exchange through Maxim Group LLC.

How were the 32,077 TSHA shares being sold acquired?

The 32,077 shares were acquired on 01/23/2026 as an RSU award from the issuer, described as a vested grant settled in stock in consideration for the reporting person’s continued service as an employee.

How many TSHA common shares were outstanding according to this notice?

The filing states that 273,919,373 shares of the issuer’s common stock were outstanding for this class at the time referenced.

Who is the broker handling this proposed TSHA share sale?

The proposed sale is to be handled by Maxim Group LLC, located at 300 Park Avenue, 16th Floor, New York, NY 10022.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/23/2026 - 08:01 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001977343
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TAYSHA GENE THERAPIES, INC.
SEC File Number	001-39536
Address of Issuer	3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TEXAS 75247
Phone	214-612-0000
Name of Person for Whose Account the Securities are To Be Sold	Emily McGinnis
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Affiliate-Chief Pat. Adv. & Ext. Aff. Off.

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Maxim Group LLC 300 Park Avenue, 16th Floor New York NY 10022	32077	163271.93	273919373	01/23/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/23/2026	RSU Award	Issuer			32077	01/23/2026	Vested grant settled in stock; consideration was Reporting Person's continued service as an employee of the Issuer.

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
Date of Notice	01/23/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Emily McGinnis
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)